Literature DB >> 28138937

Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer.

G Turine1, A Peeters2, C Hermans3, S Eeckhoudt4, T Duprez5.   

Abstract

Entities:  

Keywords:  Dabigatran; Idarucizumab; Intravenous thrombolysis; Ischemic stroke

Mesh:

Substances:

Year:  2017        PMID: 28138937     DOI: 10.1007/s13760-017-0751-5

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


× No keyword cloud information.
  6 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.

Authors:  Sergio Agosti; Laura Casalino; Enrico Rocci; Gabriele Zaccone; Eugenia Rota
Journal:  J Med Case Rep       Date:  2017-08-15

Review 3.  Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.

Authors:  Slaven Pikija; Laszlo K Sztriha; J Sebastian Mutzenbach; Stefan M Golaszewski; Johann Sellner
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

4.  Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.

Authors:  Senta Frol; Dimitrios Sagris; Janja Pretnar Oblak; Mišo Šabovič; George Ntaios
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

5.  Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations.

Authors:  Kazunori Toyoda; Hiroshi Yamagami; Masatoshi Koga
Journal:  J Stroke       Date:  2018-09-30       Impact factor: 6.967

6.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.